Researchers find relief for chronic pain

Jan 22, 2008

Researchers in the Department of Medicine and Department of Neurosciences at Mount Sinai School of Medicine have discovered that chronic pain can be successfully treated with novel targeted gene therapy. In an effort to find a more effective treatment for chronic pain, researchers at Mount Sinai developed a gene therapy technique that simulates the pain-killing effect of opiate drugs.

In the new study “Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain” published in the January 22, 2008 issue of the Proceedings of the National Academy of Sciences, researchers suggest that gene therapy for pain might in the future become a treatment alternative for patients with severe chronic pain.

“Fifty million Americans suffer from chronic pain. Chronic pain patients often do not experience satisfactory pain relief from available treatments due to poor efficacy or intolerable side effects like extreme sleepiness, mental clouding, and hallucinations,” said Dr. Andreas Beutler, MD, principal investigator of the study and Assistant Professor of Medicine/ Hematology And Medical Oncology at Mount Sinai School of Medicine.

Mount Sinai researchers designed a viral vector to carry the prepro-b-endorphin gene into primary sensory neurons in order to activate opiate receptors selectively, in a rat model. The agents were delivered directly into the spinal fluid of rats via a lumbar puncture, or spinal tap with only one injection. Results showed that the rats remained symptom-free for an extended period of time.

“Our research found that treating chronic pain with Adeno-Associated Virus vector-based gene therapy allows for pain relief for more than three months after a single injection, targeting selectively the pain gate. The technique worked successfully with opioid- and non-opioid therapeutic genes,” said Dr. Beutler. “Targeted gene therapy will likely avoid the unwanted side effects associated with opioid painkillers such as morphine. Based on our findings, this targeted gene therapy via lumbar puncture appears to be a promising candidate for bench-to-bedside research that might ultimately be tested in patients with intractable chronic pain, e.g., to help patients suffering from severe pain due to advanced cancer.”

Source: The Mount Sinai Hospital

Explore further: Stem cells faulty in Duchenne muscular dystrophy

add to favorites email to friend print save as pdf

Related Stories

Controlling genes with your thoughts

Nov 11, 2014

Researchers led by ETH Zurich professor Martin Fussenegger have constructed the first gene network that can be controlled by our thoughts. The inspiration for this development was a game that picks up brainwaves ...

Researchers find candidate gene culprits for chronic pain

May 06, 2010

Chronic pain severely limits patients' quality of life and is among the cost drivers in U.S. health care. Patients can suffer pain without an apparent cause and often fail to respond to available treatments. Mayo Clinic researchers ...

Gene therapy for chronic pain gets first test in people

Sep 15, 2008

This week, University of Michigan scientists will begin a phase 1 clinical trial for the treatment of cancer-related pain, using a novel gene transfer vector injected into the skin to deliver a pain-relieving ...

Recommended for you

Stem cells faulty in Duchenne muscular dystrophy

18 hours ago

Like human patients, mice with a form of Duchenne muscular dystrophy undergo progressive muscle degeneration and accumulate connective tissue as they age. Now, researchers at the Stanford University School of Medicine have ...

Here's how the prion protein protects us

23 hours ago

The cellular prion protein (PrPC) has the ability to protect the brain's neurons. Although scientists have known about this protective physiological function for some time, they were lacking detailed knowledge ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.